MSR67 Bridging and Validation of a Thyroid Eye Disease (TED) Specific Quality of Life (QOL) Questionnaire to Utility Values Assessed By a Time Trade-Off (TTO) Analysis

Abstract

TED, an autoimmune, inflammatory disease, is characterized by retro-orbital tissue expansion and devastating changes in facial appearance and visual function. The Graves’ Ophthalmopathy QOL (GO-QOL) questionnaire is TED specific but has not been mapped to health state utility (HSU) scores. Recently, mean score for moderate-severe TED was assessed as 0.44. To quantify QALY improvements with teprotumumab, we correlated and bridged GO-QOL values with TTO-derived utility scores.